ID: ALA5185647

Max Phase: Preclinical

Molecular Formula: C30H29F3N6O2

Molecular Weight: 562.60

Representations

Canonical SMILES:  CNC(=O)c1ccc(-c2ccc(=O)n(CCc3ccc4ncc(N5CC6CNCC6C5)cc4c3)n2)cc1C(F)(F)F

Standard InChI:  InChI=1S/C30H29F3N6O2/c1-34-29(41)24-4-3-19(12-25(24)30(31,32)33)27-6-7-28(40)39(37-27)9-8-18-2-5-26-20(10-18)11-23(15-36-26)38-16-21-13-35-14-22(21)17-38/h2-7,10-12,15,21-22,35H,8-9,13-14,16-17H2,1H3,(H,34,41)

Standard InChI Key:  QZAJKFYDPRILPN-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 562.60

Molecular Weight (Monoisotopic): 562.2304

AlogP: 3.74

#Rotatable Bonds: 6

Polar Surface Area: 92.15

Molecular Species: BASE

HBA: 7

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 13.76

CX Basic pKa: 11.12

CX LogP: 3.00

CX LogD: -0.11

Aromatic Rings: 4

Heavy Atoms: 41

QED Weighted: 0.37

Np Likeness Score: -1.39

References

1. Wang C, Li J, Qu L, Tang X, Song X, Yang F, Chen X, Lin Q, Lin W, Zhou Y, Tu Z, Chen Y, Zhang Z, Lu X..  (2022)  Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment.,  65  (22.0): [PMID:36355693] [10.1021/acs.jmedchem.2c00981]

Source

Source(1):

• Scientific Literature